Catalyst Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Catalyst Pharmaceuticals CEO ist Rich Daly , ernannt in Jan 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.2% der Aktien des Unternehmens, im Wert von $5.04M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.9 Jahre bzw. 11.9 Jahre.

Wichtige Informationen

Rich Daly

Geschäftsführender

US$14.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	3.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	11.9yrs

Jüngste Management Updates

Recent updates

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Nov 13

Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings

Nov 07

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

Geschäftsführer

Rich Daly (63 yo)

less than a year

Amtszeit

US$14,076,923

Vergütung

Mr. Richard John Daly, also known as Rich, MBA, had been an Independent Director at Catalyst Pharmaceuticals, Inc. from February 2015 until January 1, 2024 and serves as its Chief Executive Officer and Dir...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Richard John Daly	President	less than a year	US$14.08m	0.20% $ 5.0m
Steven Miller	Executive VP	15.1yrs	US$3.40m	0.57% $ 14.5m
Gary Ingenito	Chief Medical & Regulatory Officer	9.4yrs	US$2.37m	0.043% $ 1.1m
Jeffrey Del Carmen	Executive VP & Chief Commercial Officer	4.4yrs	US$2.51m	0.010% $ 265.7k
Michael Kalb	Executive VP	less than a year	keine Daten	keine Daten
Mary Coleman	VP & Head of Investor Relations	3.3yrs	keine Daten	keine Daten
Brian Elsbernd	Chief Compliance Officer & Chief Legal Officer	8.8yrs	US$353.27k	0.10% $ 2.7m
Pete Curry	Vice President of Sales	4.4yrs	keine Daten	keine Daten
Stanley Iyadurai	Senior Vice President of Medical Affairs & Drug Discovery	1.7yrs	keine Daten	keine Daten
Preethi Sundaram	Chief Strategy Officer	3.3yrs	US$1.70m	0.021% $ 548.5k
Philip Schwartz	Corporate Secretary	no data	keine Daten	keine Daten

3.9yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrenes Management: CPRXDas Führungsteam des Unternehmens gilt als erfahren (3.9 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Richard John Daly	President	9.8yrs	US$14.08m	0.20% $ 5.0m
David Tierney	Independent Director	22.1yrs	US$370.99k	0.29% $ 7.5m
Patrick McEnany	Co-Founder & Chairman	22.8yrs	US$2.15m	3.75% $ 96.2m
Donald Denkhaus	Independent Director	9.8yrs	US$376.24k	0.37% $ 9.4m
Charles O'Keeffe	Lead Independent Director	19.9yrs	US$397.24k	0.57% $ 14.7m
Eugene Laska	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Robert Fechtner	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Jonathan Brodie	Chairman of Scientific Advisory Board	no data	keine Daten	keine Daten
Molly Harper	Independent Director	3.4yrs	US$363.12k	keine Daten
Richard Silverman	Member of Scientific Advisory Board	14yrs	keine Daten	keine Daten
Tamar Thompson	Independent Director	1.5yrs	US$610.43k	keine Daten

11.9yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: CPRXDie Vorstandsmitglieder sind sehr erfahren ( 11.9 ).

Catalyst Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Co-Founder & Chairman notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Executive VP recently sold US$3.1m worth of stock

Executive VP notifies of intention to sell stock

Chief Medical & Regulatory Officer notifies of intention to sell stock

Chief Medical & Regulatory Officer notifies of intention to sell stock

Recent updates

Co-Founder & Chairman notifies of intention to sell stock

We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Independent Director notifies of intention to sell stock

Executive VP recently sold US$3.1m worth of stock

Executive VP notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 16%

Chief Medical & Regulatory Officer notifies of intention to sell stock

Price target increased by 8.4% to US$29.57

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals: New Products In Proving Phase

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Independent Director exercised options and sold US$481k worth of stock

Insider exercised options and sold US$747k worth of stock

Investor sentiment improves as stock rises 15%